Jefferies Downgrades XPeng to Underperform, Lowers Price Target to $4.2

Jefferies analyst Johnson Wan downgrades XPeng (NYSE:XPEV) from Hold to Underperform and lowers the price target from $18.6 to $4.2.

Jefferies analyst Johnson Wan downgrades XPeng (NYSE:XPEV) from Hold to Underperform and lowers the price target from $18.6 to $4.2.

Total
0
Shares
Related Posts
Read More

This Latin American Cannabis Co. Plans To Expand In Thailand Amid Significant Shifts In Weed Regulation Landscape

PharmaCielo revealed its plans to acquire cannabis operations in Thailand.On Wednesday, the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., said it has signed a binding letter of intent to enter a proposed transaction to acquire 100% of the issued and outstanding shares of Siam Ventures Corporation in exchange for common shares of PharmaCielo equaling to CA$3 million ($2.2 million).PharmaCielo also revealed it's undertaking a non-brokered private placement of 9,090,909 units at CA$0.2 per unit. Under the deal, the sum will be payable on closing by way of the issuance of 13,636,363 PharmaCielo Shares to the Siam Ventures' shareholders on a pro-rata basis.

PCLOF